Research press release




骨量の減少と体内の内臓脂肪量の増加は、閉経の一般的な特徴だが、今回、Mone Zaidiたちの研究グループは、下垂体ホルモンの一種である卵胞刺激ホルモンに対する抗体療法を適用した結果、卵巣を切除したマウスの骨量が増加し、肥満が減少する過程を明らかにした。この抗体療法は、高脂肪食を与えた標準的なマウスの肥満蓄積も減らした。この抗体療法を受けたマウスは、酸素消費、身体活動、褐色脂肪とベージュ脂肪細胞での熱産生が増加した。


A newly discovered antibody, trialled in a mouse model of menopause, may help to boost bone mass and reduce body fat, a paper published online this week in Nature suggests. Further research is needed to determine whether these findings will translate to humans, but the study could aid the development of a single drug to help treat both post-menopausal osteoporosis and weight gain, and obesity in general.

Loss of bone mass and increased levels of visceral body fat are common features of menopause. Here, Mone Zaidi and colleagues show how treatment with an antibody against part of the pituitary hormone follicle-stimulating hormone increases bone mass and reduces adiposity in mice that have had their ovaries removed. The antibody treatment also reduced adiposity in regular mice fed a high-fat diet. Mice treated in this way showed increases in oxygen consumption, physical activity and thermogenesis (heat production) in brown and beige fat.

Current anti-obesity treatments, which tend to work by reducing appetite or blocking nutrient absorption, have limited efficacy and can cause side effects. The authors suggest that a humanized version of the newly reported antibody might also be of potential use in other conditions involving visceral adiposity, such as metabolic syndrome, cardiovascular disease, cancer, diabetes and polycystic ovary disease.

doi: 10.1038/nature22342

「Nature 関連誌注目のハイライト」は、ネイチャー広報部門が報道関係者向けに作成したリリースを翻訳したものです。より正確かつ詳細な情報が必要な場合には、必ず原著論文をご覧ください。

メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週最新のNature 関連誌のハイライトを皆様にお届けいたします。